AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03706157
Drug: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
Trial: NCT02971384
Drug: Echinaforce
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05237115
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 40mg 1tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or Bacillus coagulans tablets 350mg 3 capsules BID and Clostridium butyricum capsule 420mg 3 capsules BID as a dose given for bismuth-containing quadruple therapy or probiotics combined with triple therapy.
Trial: NCT04207177
Drug: Mycophenolate Mofetil 500 mg Tab
RxNorm normalized name: mycophenolate mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.
Trial: NCT01899118
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825mg/m2 bid d1-5/w,1-5w
Trial: NCT02105636
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05237115
Drug: Bacillus clotting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given for 14 days at a dose of Bacillus coagulans tablets 350mg 3 capsules, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Trial: NCT00288184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02256774
Drug: Combivir®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00434031
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00434031
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00163566
Drug: Dihydrotestosterone (0.7%) in hydroalcoholic gel
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
Trial: NCT00356447
Drug: Estradiol/DRSP (Angeliq, BAY86-4891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
Trial: NCT00356447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same administration.
Trial: NCT00484471
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to aripiprazole, 22 weeks
Trial: NCT00141518
Drug: Levodopa-carbidopa intestinal gel (LCIG)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00410631
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00920153
Drug: ABVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00410631
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00920153
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01333423
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
Trial: NCT01425736
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
Trial: NCT00400075
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00400075
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03250689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be available as oval shaped, white film coated tablets.
Trial: NCT03250689
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
Trial: NCT03250689
Drug: Inhaled COPD maintenance medication
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
Trial: NCT04331691
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
Trial: NCT04331691
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
Trial: NCT01625871
Drug: tablets artemether/lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six doses of oral tablets of artemether/lumefantrine
Trial: NCT00542893
Drug: Genasense® (G3139, oblimersen sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00542893
Drug: Genasense followed by DTIC; then DTIC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
Trial: NCT00542893
Drug: DTIC alone; then Genasense followed by DTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
Trial: NCT01749111
Drug: ARM B Calcineurin inhibitor and methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
Trial: NCT01545388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match metformin 250 mg tablets, orally, for 24 weeks
Trial: NCT00437164
Drug: Oral GW677954 Capsules (15 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01038687
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01807221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03093519
Drug: KHK6640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT03093519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT01619865
Drug: 68Ga-DOTATOC PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
Trial: NCT00859222
Drug: LBH589
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01737424
Drug: LC28-0126
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126
Trial: NCT01737424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03207191
Drug: F16IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
Trial: NCT00001955
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00969826
Drug: GCPGC, Neulasta, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
Trial: NCT01406119
Drug: ABT-806
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-806 will be administered by intravenous infusion.
Trial: NCT03307005
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule one per night taken for 7 nights
Trial: NCT03670095
Drug: Lactose-free memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-free memantine tablet, 10 mg; orally as a single dose
Trial: NCT00601315
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04488770
Drug: GSK3882347
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule of 10-200mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.
Trial: NCT04488770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching strength placebo capsules will be provided
Trial: NCT04192214
Drug: BC 007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1350 mg of BC 007
Trial: NCT02162160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creme without probiotics applied in same manner
Trial: NCT03468725
Drug: XPF-008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule filled with XEN1101
Trial: NCT02664077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
Trial: NCT01051479
Drug: C11-Choline
RxNorm normalized name: Choline C11
DrugBank: Choline C-11 (DB09563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
Trial: NCT03224793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT03449251
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03325335
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
Trial: NCT00373295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01129245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical to celecoxib
Trial: NCT02925858
Drug: Normal Saline Flush, 0.9% Injectable Solution_#1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion mimicking infusion rate of ketamine for a given weight
Trial: NCT01026948
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
Trial: NCT01718236
Drug: Succinylcholine + Neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
Trial: NCT01012414
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02291289
Drug: FOLFOX induction regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.
Trial: NCT04177043
Drug: DAAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with different regiments with DAAs
Trial: NCT01127763
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00765856
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone ER dosing adjustments made under the direction of the Investigator during the Titration Period.~Oxymorphone IR (Opana) IR 5mg tablet - used as rescue medications
Trial: NCT02571153
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline 0.9% 5 mL
Trial: NCT04232345
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be fasted for at least 10 hours before receiving the AZD4831 in the form of an oral suspension.
Trial: NCT04232345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be fasted for at least 10 hours before receiving the placebo in the form of an oral suspension.
Trial: NCT01944436
Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01715233
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400mg/m2 on Day 1
Trial: NCT01715233
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
Trial: NCT02198846
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
Trial: NCT02936375
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1g/m², every 4 weeks, intravenous
Trial: NCT02936375
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2mg/kg·d, once a day, orally administrated
Trial: NCT02936375
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
Trial: NCT04443647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT00918593
Drug: Electrochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
Trial: NCT00810199
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Approximately 15-17 mg methotrexate capsule orally once a week.
Trial: NCT00810199
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching methotrexate capsule taken orally once a week.
Trial: NCT01966172
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral ibuprofen 400mg 4 times daily
Trial: NCT04312243
Drug: Inhaled nitric oxide gas
RxNorm normalized name: nitric oxide / nitrogen Gas for Inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: a SARS-CoV2 rt-PCR will be performed if symptoms arise. Treatment group: the subjects will breathe NO at the beginning of the shift and before leaving the hospital. Inspired NO will be delivered at 160 parts per million (ppm) for 15 minutes in each cycle. A SARS-CoV-2 rt-PCR will be performed if symptoms arise. Safety: Oxygenation and methemoglobin levels will be monitored via a non-invasive CO-oximeter. If methemoglobin levels rise above 5% at any point of the gas delivery, inhaled NO will be halvened. NO2 gas will be monitored and maintained below 5 ppm.
Trial: NCT01789788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, multiple doses
Trial: NCT01789788
Drug: RO6811135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending doses
Trial: NCT01967589
Drug: NNC0113-0987
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
Trial: NCT01967589
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily doses for oral administration
Trial: NCT01121939
Drug: Sandostatin LAR® Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
Trial: NCT00914134
Drug: Levodopa infusion
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
Trial: NCT01441128
Drug: PF-02341066/PF-00299804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined PF-02341066 and PF-00299804
Trial: NCT02291289
Drug: 5-FU/LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.
Trial: NCT02291289
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.
Trial: NCT01441128
Drug: PF-02341066/PF-00299804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
Trial: NCT00650221
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 80 mg immediate-release oral tablet
Trial: NCT00650221
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 80 mg immediate-release tablet
Trial: NCT01137253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response to intrabrachial vasodilators during IV saline infusion
Trial: NCT00002822
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002822
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01106131
Drug: CKD-501 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.